186 related articles for article (PubMed ID: 20169510)
1. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.
Ananyeva NM; Lee TK; Jain N; Shima M; Saenko EL
Semin Thromb Hemost; 2009 Nov; 35(8):735-51. PubMed ID: 20169510
[TBL] [Abstract][Full Text] [Related]
2. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.
Gomperts ED; Astermark J; Gringeri A; Teitel J
Blood Rev; 2008 Feb; 22 Suppl 1():S1-11. PubMed ID: 18485996
[TBL] [Abstract][Full Text] [Related]
3. New approaches to using FEIBA in the treatment of inhibitor patients.
Berntorp E; Gringeri A; Leissinger C; Négrier C; Key N
Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():22-7. PubMed ID: 16804832
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
[TBL] [Abstract][Full Text] [Related]
5. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
6. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
8. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.
Tjønnfjord GE; Holme PA
Vasc Health Risk Manag; 2007; 3(4):527-31. PubMed ID: 17969383
[TBL] [Abstract][Full Text] [Related]
9. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
[TBL] [Abstract][Full Text] [Related]
10. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
[TBL] [Abstract][Full Text] [Related]
11. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
Berntorp E; Collins P; D'Oiron R; Ewing N; Gringeri A; Négrier C; Young G
Haemophilia; 2011 Jan; 17(1):e202-10. PubMed ID: 20825500
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
Astermark J; Donfield SM; DiMichele DM; Gringeri A; Gilbert SA; Waters J; Berntorp E;
Blood; 2007 Jan; 109(2):546-51. PubMed ID: 16990605
[TBL] [Abstract][Full Text] [Related]
13. Successful total hip replacement with sequential administration of bypassing agents in an adolescent boy with hemophilia A and high inhibitor titers.
Kaya Z; Orhan Ö; Turanlı S; Yenicesu İ; Koçak Ü; Gürsel T
Blood Coagul Fibrinolysis; 2017 Jul; 28(5):419-422. PubMed ID: 28079537
[TBL] [Abstract][Full Text] [Related]
14. Monitoring inhibitor patients with the right assays.
Barrowcliffe TW
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S25-30. PubMed ID: 18544420
[TBL] [Abstract][Full Text] [Related]
15. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.
López-Fernández MF; Altisent Roca C; Álvarez-Román MT; Canaro Hirnyk MI; Mingot-Castellano ME; Jiménez-Yuste V; Cid Haro AR; Pérez-Garrido R; Sedano Balbas C
Thromb Haemost; 2016 May; 115(5):872-95. PubMed ID: 26842562
[TBL] [Abstract][Full Text] [Related]
16. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
[No Abstract] [Full Text] [Related]
17. Management of factor VIII inhibitors.
Acharya SS; DiMichele DM
Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
Doshi BS; Gangadharan B; Doering CB; Meeks SL
PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors in haemophilia A: current management and open issues.
Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
[TBL] [Abstract][Full Text] [Related]
20. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
